Does RUXOLITINIB Cause Concomitant disease aggravated? 142 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 142 reports of Concomitant disease aggravated have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.2% of all adverse event reports for RUXOLITINIB.
142
Reports of Concomitant disease aggravated with RUXOLITINIB
0.2%
of all RUXOLITINIB reports
47
Deaths
79
Hospitalizations
How Dangerous Is Concomitant disease aggravated From RUXOLITINIB?
Of the 142 reports, 47 (33.1%) resulted in death, 79 (55.6%) required hospitalization, and 9 (6.3%) were considered life-threatening.
Is Concomitant disease aggravated Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 142 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Concomitant disease aggravated?
SACUBITRIL\VALSARTAN (533)
SECUKINUMAB (461)
FINGOLIMOD (425)
MACITENTAN (286)
OMALIZUMAB (186)
SELEXIPAG (166)
METHOTREXATE (150)
OCTREOTIDE (125)
BOSENTAN (123)
EVEROLIMUS (123)
Which RUXOLITINIB Alternatives Have Lower Concomitant disease aggravated Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE